A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease.
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2010
At a glance
- Drugs AZD 7295 (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Arrow Therapeutics
- 02 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Apr 2010 Actual patient number (31) added as reported by ClinicalTrials.gov.
- 17 Feb 2010 Planned end date changed from 1 Nov 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.